Higher inflammatory burden tracked with prevalent CKD in hypertensive adults
A routine blood count-derived marker was associated with chronic kidney disease in adults living with hypertension. In a nationally representative NHANES sample of 18,675 participants, higher systemic immune-inflammation index values tracked with greater odds of prevalent chronic kidney disease, adding to the growing view that low-grade inflammation is not just a bystander in hypertensive organ damage.
The analysis used data from 2001 through 2020 and applied NHANES examination weights, strata, and primary sampling units, a design choice that strengthens population-level interpretability. After full adjustment, each 1-standard-deviation increase in log1p-transformed SII corresponded to an odds ratio of 1.10 for CKD, with a 95% confidence interval of 1.04 to 1.17 and a P value of 0.002. Participants in the highest SII quartile also carried higher odds of CKD than those in the lowest quartile, with an odds ratio of 1.23.
The signal was not jagged or confined to a single analytical lens. Restricted cubic spline modeling showed a significant overall association, while the test for nonlinearity was not significant, suggesting a largely monotonic relationship across the observed range rather than a threshold effect. In practical terms, higher inflammatory activity rose in step with kidney disease prevalence instead of waiting for a sharp inflection point.
Why a complete blood count marker may track kidney injury
SII combines neutrophils, lymphocytes, and platelets into a single index, making it a crude but biologically plausible proxy for systemic immune activation. In hypertension, persistent inflammatory signaling can damage the microvasculature, worsen endothelial dysfunction, and accelerate glomerular stress. Platelet activation and neutrophil-driven inflammatory cascades may also contribute to vascular remodeling and renal hypoperfusion, while lymphocyte suppression can reflect broader immune imbalance.
These pathways fit the clinical pattern seen here. Hypertension and CKD feed one another, with blood pressure burden injuring renal tissue and declining kidney function in turn amplifying volume overload, neurohormonal activation, and vascular injury. A marker that captures both immune and inflammatory tone may therefore track the same pathophysiology that links the two conditions at the bedside.
One sentence captures the practical implication: a standard CBC may carry more renal information than its traditional role suggests.
The association proved stronger among participants younger than 60 years, with an interaction P value of 0.017. That age pattern raises the possibility that inflammatory burden may be more informative earlier in the course of hypertensive disease, before decades of comorbidity, medication exposure, and structural kidney damage blur the signal. Younger adults with hypertension and elevated SII may represent a subgroup in whom inflammatory biology is already leaving a measurable imprint on renal status.
Propensity weighting held the association in place
The investigators did not rely on a single modeling strategy. They repeated the analysis using propensity score weighting approaches aimed at the average treatment effect, the average treatment effect among the treated, and the average treatment effect in the overlap population. Across these methods, the association persisted, and overlap weighting yielded an odds ratio of 1.192 for high versus low SII, with a 95% confidence interval of 1.064 to 1.334 and a P value of 0.002.
This consistency matters because observational work can shift when covariate balance changes. Here, the result stayed directionally stable across multiple weighting frameworks, which makes residual confounding less likely to explain the full finding, even though it cannot be eliminated in a cross-sectional design. The data support association, not causation, and the kidney outcome and inflammatory marker were assessed at the same point in time.
The study also sits within a larger pattern of NHANES-based work exploring inflammatory indices and chronic disease. SII has already been linked with hypertension and cardiovascular-kidney-metabolic outcomes in other analyses, and this report extends the same marker into the specific setting of hypertensive CKD prevalence. The appeal of the index is obvious: it is inexpensive, readily available, and built from routine laboratory values that most clinicians already have.
What clinicians can do with this signal now
No kidney-protective intervention should be chosen on SII alone. Still, elevated SII may help identify hypertensive patients who deserve closer scrutiny for renal disease, particularly if they are younger and otherwise appear clinically stable. In a setting where CKD often progresses quietly, a marker embedded in the standard complete blood count could serve as an early prompt to check estimated glomerular filtration rate, albuminuria, and other renal risk factors more deliberately.
The study leaves several questions unresolved. Cross-sectional data cannot determine whether high SII precedes kidney disease, follows it, or reflects both processes at once. The analysis also does not establish whether lowering inflammation would reduce CKD risk in hypertensive adults, or whether SII adds enough discrimination to improve routine risk prediction beyond standard clinical variables. A prospective cohort or intervention study would be needed to determine whether this biomarker is only a mirror of risk or a meaningful target for action.
Funding came from Chinese national and institutional sources, and the NHANES protocol had ethics approval with written informed consent. The central message is straightforward: in adults with hypertension, higher systemic immune-inflammation index values were associated with prevalent chronic kidney disease, with the strongest signal in those under 60 years of age and a result that remained stable across several propensity score weighting approaches.